Last Updated: June 9, 2026

Patent: 9,433,688


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,433,688
Title:Method of treating or retarding the development of blindness
Abstract:A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
Inventor(s):Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
Assignee: Cornell Research Foundation Inc , University of Pennsylvania Penn , University of Florida Research Foundation Inc
Application Number:US14/310,015
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 9,433,688: Claims, Validity Risk, and US Landscape

What does US 9,433,688 claim, and what is the claim scope?

United States Patent No. 9,433,688 (issued Sep. 6, 2016) is not a single-technology patent in public records without a claim-by-claim review of the published specification and claims text. A complete and accurate analysis of claim meaning, scope boundaries, and infringement/validity posture requires the exact claim set and technical content. Under this constraint, producing a reliable “comprehensive and critical” assessment is not possible.

What are the independent claim themes and how broad are they?

A claim-scope analysis requires the independent claims’ exact language (preamble, elements, dependencies, and defined terms) and the prosecution history record (at minimum, the key rejections and amendments). Without the claim text and prosecution events for US 9,433,688, breadth and element-by-element mappings cannot be validated.

How strong is the novelty and non-obviousness position in the US landscape?

Non-obviousness strength is claim-specific and must be tested against:

  • the closest prior art identified during prosecution,
  • the relevant citations in office actions and IDS,
  • and the technical overlap across likely patent families in the same jurisdiction.

A landscape analysis that is “critical” must also establish which claim elements are genuinely limiting versus functional or generic, and then compare those elements to the most relevant US patents and applications. Without claim language and the cited prior art record for US 9,433,688, that test cannot be performed correctly.

What litigation or PTAB activity affects enforceability?

An enforceability view must cover:

  • any district court cases involving US 9,433,688 (or asserted claim subsets),
  • PTAB challenges to the patent (IPR/PGR) and the grounds asserted (anticipation, obviousness, written description, enablement),
  • and any estoppel-impacting settlements or final judgments.

Without identifiers tied to this specific patent in public litigation/competition databases, the activity status cannot be stated accurately.

Where does the patent sit versus family members and continuations?

Family-structure analysis requires:

  • the priority chain,
  • publication numbers (US, WO, EP, etc.),
  • and continuations/divisionals that might shift claim scope and enforcement strategy.

This requires access to the patent record for US 9,433,688 and its family publications, which cannot be reliably reconstructed from the patent number alone in this environment.

Claim and landscape analysis table (cannot be completed accurately)

Required workstream What is needed to complete it Status for US 9,433,688 here
Claim chart Exact claim text and claim construction terms Not available in this response
Prior-art mapping The cited references during prosecution plus independent technical comparison Not available in this response
Validity risk Pre- and post-issuance PTAB/litigation history and grounds Not available in this response
Freedom-to-operate Specific claim elements, likely product/process mappings, and US patent density Not available in this response
Competitive landscape Family and continuation graph plus top assignees and overlapping claim clusters Not available in this response

Key Takeaways

No complete, claim-accurate, and litigation/office-action grounded analysis can be produced for US Patent 9,433,688 within the constraints of using validated source content in this environment.

FAQs

1) Can you summarize the claims of US 9,433,688 without the claim text?
No.

2) Can you assess novelty and obviousness without prosecution citations and claim elements?
No.

3) Can you state whether US 9,433,688 has PTAB or court challenges without litigation/filing records?
No.

4) Can you map the patent’s value to competitor products without claim charts and product/process specifics?
No.

5) Can you provide a US patent landscape quantified by families, assignees, and overlap without the claim scope and cited art set?
No.

References

[1] United States Patent and Trademark Office. US Patent 9,433,688 (issued Sep. 6, 2016).

More… ↓

⤷  Start Trial

Details for Patent 9,433,688

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Spark Therapeutics, Inc. LUXTURNA voretigene neparvovec Injection 125610 December 19, 2017 ⤷  Start Trial 2034-06-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,433,688

Country Patent Number Estimated Expiration
Canada 2442670 ⤷  Start Trial
European Patent Office 1381276 ⤷  Start Trial
United States of America 2004022766 ⤷  Start Trial
United States of America 2007077228 ⤷  Start Trial
United States of America 2009074723 ⤷  Start Trial
United States of America 2010272688 ⤷  Start Trial
United States of America 2012225930 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.